<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">r-n-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский неврологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian neurological journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2658-7947</issn><issn pub-type="epub">2686-7192</issn><publisher><publisher-name>МИА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30629/2658-7947-2024-29-5-23-30</article-id><article-id custom-type="elpub" pub-id-type="custom">r-n-j-619</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Роль нейротрофических факторов в  ходе восстановительной терапии у  пациентов с  детским церебральным параличом</article-title><trans-title-group xml:lang="en"><trans-title>The role of neurotrophic factors during rehabilitation therapy in patients with cerebral palsy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0958-130X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корсунская</surname><given-names>Л. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Korsunskaya</surname><given-names>L. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Симферополь</p></bio><bio xml:lang="en"><p>Simferopol</p></bio><email xlink:type="simple">neurocrimea@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4590-3580</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Агеева</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Ageeva</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Симферополь</p></bio><bio xml:lang="en"><p>Simferopol</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6996-4823</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ларина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Larina</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Симферополь</p></bio><bio xml:lang="en"><p>Simferopol</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Крымский федеральный университет им. В.И. Вернадского, Медицинский институт им. С.И. Георгиевского<country>Россия</country></aff><aff xml:lang="en">V.I. Vernadsky Crimean Federal University, Medical Institute named after S.I. Georgievsky<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>06</day><month>01</month><year>2025</year></pub-date><volume>29</volume><issue>5</issue><fpage>23</fpage><lpage>30</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Корсунская Л.Л., Агеева Е.С., Ларина Н.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Корсунская Л.Л., Агеева Е.С., Ларина Н.В.</copyright-holder><copyright-holder xml:lang="en">Korsunskaya L.L., Ageeva E.S., Larina N.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.r-n-j.com/jour/article/view/619">https://www.r-n-j.com/jour/article/view/619</self-uri><abstract><p>Результаты исследования динамики концентрации нейротрофических факторов (НТФ) в крови пациентов с детским церебральным параличом (ДЦП) после применения методики «неинвазивный интерфейс мозг-компьютер-экзокисть» с биологической обратной связью продемонстрировали снижение уровня НТФ на 10-й день после проведения реабилитационных тренингов, что сопровождалось улучшением двигательных, когнитивных функций и эмоционального статуса пациентов. При этом различные НТФ продемонстрировали разный уровень изменения концентрации. Проведен анализ литературы, посвященной механизмам влияния НТФ на процессы нейропластичности. В обзоре представлены результаты исследований механизмов влияния НТФ на различные функции мозга и способность проникать через гематоэнцефалический барьер. Анализ данных литературы свидетельствует об активном вовлечении НТФ в механизмы функциональной перестройки и их возможной роли в восстановлении двигательной активности у детей с ДЦП, положительном влиянии на когнитивные функции и эмоциональный статус.</p></abstract><trans-abstract xml:lang="en"><p>Blood concentration of neurotrophic factors (NTF) in patients with cerebral palsy after the use of the “non-invasive brain-computer-exohand interface” technique demonstrated a decrease in the level of NTFs on the 10th day after rehabilitation training, which was accompanied by an improvement in motor, cognitive functions and emotional status of patients. Moreover, different NTFs demonstrated different levels of concentration changes. The literature base about influence of NTFs on the mechanisms of neuroplasticity was analyzed. The review presents the results of studies on the therapeutic targets of NTFs and their different abilities to penetrate the blood-brain barrier, which apparently explains their participation in the processes of neuroplasticity. Analysis of literature data indicates the active involvement of NTF in the mechanisms of functional restructuring and their possible role in restoring motor activity in children with cerebral palsy, positive effect on cognitive functions and emotional status.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нейротрофические факторы</kwd><kwd>детский церебральный паралич</kwd><kwd>восстановительная терапия</kwd><kwd>экзокисть</kwd></kwd-group><kwd-group xml:lang="en"><kwd>neurotrophic factors</kwd><kwd>cerebral palsy</kwd><kwd>rehabilitation therapy</kwd><kwd>exohand</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Исследование поддержано грантом Российского научного фонда и Республики Крым №22-15-20035, https://rscf.ru/project/22-15-20035.</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>The study was supported by the Russian Science Foundation and Republic of Crimea grant 22-15-20035. https://rscf.ru/project/22-15-20035</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ларина Н.В., Гордиенко А.И., Корсунская Л.Л., Химич Н.В. Роль нейротрофических факторов в процессе реабилитации детей с детским церебральным параличом. Неврология, нейропсихиатрия, психосоматика. 2022;14(6):12–19. https://doi.org/10.14412/2074-2711-2022-6-12-19</mixed-citation><mixed-citation xml:lang="en">Larina N.V., Gordienko A.I., Korsunskaya L.L., Khimich N.V. The role of neurotrophic factors in the rehabilitation of children with cerebral palsy. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):12–19. (In Russ.) https://doi.org/10.14412/2074-2711-2022-6-12-19</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Соколова М.Г., Алексеева Т.М., Лобзин С.В., Демешонок В.С., Никишина О.А., Ульянова Н.В. Нейротрофические факторы. Перспективы применения в клинической неврологии // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2014;6(3):75–81 Режим доступа https://cyberleninka.ru/article/n/neyrotroficheskie-faktory-perspektivy-primeneniya-v-klinicheskoy-nevrologii.</mixed-citation><mixed-citation xml:lang="en">M.G. Sokolova, Т.М. Alekseeva, S.V. Lobzin, V.S. Demeshonok, О.А. Nikishina, N.V. Ulyanova. Prospects of application of neurotrophic factors in clinical neurology. Mechnikov North-West State Medical University Bulletin, 2014;6(3):75–81 Available at: https://cyberleninka.ru/article/n/neyrotrofi cheskie-faktory-perspektivyprimeneniya-v-klinicheskoy-nevrologii</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Кулакова Е.Н., Настаушева Т.Л., Кондратьева И.В. Систематическое обзорное исследование литературы по методологии scoping review: история, теория и практика. Вопросы современной педиатрии. 2021;20(3): 210–222. https://doi.org/10.15690/vsp.v20i3/227.</mixed-citation><mixed-citation xml:lang="en">Kulakova Elena N., Nastausheva Tatjana L., Kondratjeva Inna V. Scoping Review Methodology: History, Theory and Practice. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(3):210–222. https://doi.org/10.15690/vsp.v20i3/227</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mateos-Aparicio P, Rodríguez-Moreno A. The Impact of Studying Brain Plasticity. Front Cell Neurosci. 2019;13:66. https://doi.org/10.3389/fncel.2019.00066</mixed-citation><mixed-citation xml:lang="en">Mateos-Aparicio P, Rodríguez-Moreno A. The Impact of Studying Brain Plasticity. Front Cell Neurosci. 2019;13:66. https://doi.org/10.3389/fncel.2019.00066</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998 Dec;37(12):1553–61. https://doi.org/10.1016/s0028-3908(98)00141-5</mixed-citation><mixed-citation xml:lang="en">Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998 Dec;37(12):1553–61. https://doi.org/10.1016/s0028-3908(98)00141-5</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S. Blood BDNF concentrations refl ect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14:347–353.https://doi.org/10.1017/S1461145710000738</mixed-citation><mixed-citation xml:lang="en">Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S. Blood BDNF concentrations refl ect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14:347–353.https://doi.org/10.1017/S1461145710000738</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Xhima K, Aubert I. The therapeutic potential of nerve growth factor combined with blood-brain barrier modulation by focused ultrasound for neurodegenerative disorders. Neural Regen Res. 2021 Sep;16(9):1783–1785. https://doi.org/10.4103/1673-5374.306076</mixed-citation><mixed-citation xml:lang="en">Xhima K, Aubert I. The therapeutic potential of nerve growth factor combined with blood-brain barrier modulation by focused ultrasound for neurodegenerative disorders. Neural Regen Res. 2021 Sep;16(9):1783–1785. https://doi.org/10.4103/1673-5374.306076</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Conrad Earl Johanso, John E. Donahue, Edward Stopa, Andrew Baird. Fibroblast Growth Factor And The Blood-Brain Barrier. In book: Handbook of Biologically Active Peptides, Second Edition, 2013, (pp.1449-1454) https://doi.org/10.1016/B978-012369442-3/50205-1</mixed-citation><mixed-citation xml:lang="en">Conrad Earl Johanso, John E. Donahue, Edward Stopa, Andrew Baird. Fibroblast Growth Factor And The Blood-Brain Barrier. In book: Handbook of Biologically Active Peptides, Second Edition, 2013, (pp.1449-1454) https://doi.org/10.1016/B978-012369442-3/50205-1</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pan W, Kastin AJ. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology. 2000 Sep;72(3):171–8. https://doi.org/10.1159/000054584</mixed-citation><mixed-citation xml:lang="en">Pan W, Kastin AJ. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology. 2000 Sep;72(3):171–8. https://doi.org/10.1159/000054584</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Pan W, Kastin AJ, Maness LM, Brennan JM. Saturable entry of ciliary neurotrophic factor into brain. Neurosci Lett. 1999 Mar 19;263(1):69–71. https://doi.org/10.1016/s0304-3940(99)00083-x</mixed-citation><mixed-citation xml:lang="en">Pan W, Kastin AJ, Maness LM, Brennan JM. Saturable entry of ciliary neurotrophic factor into brain. Neurosci Lett. 1999 Mar 19;263(1):69–71. https://doi.org/10.1016/s0304-3940(99)00083-x</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Poduslo JF, Curran GL. Permeability at the blood-brain and bloodnerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996 Mar;36(2):280–6. https://doi.org/10.1016/0169-328x(95)00250-v</mixed-citation><mixed-citation xml:lang="en">Poduslo JF, Curran GL. Permeability at the blood-brain and bloodnerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996 Mar;36(2):280–6. https://doi.org/10.1016/0169-328x(95)00250-v</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736. https://doi.org/10.1146/annurev.neuro.24.1.677</mixed-citation><mixed-citation xml:lang="en">Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736. https://doi.org/10.1146/annurev.neuro.24.1.677</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Keefe KM, Sheikh IS, Smith GM. Targeting Neurotrophins to Specifi c Populations of Neurons: NGF, BDNF, and NT-3 and Their Relevance for Treatment of Spinal Cord Injury. International Journal of Molecular Sciences. 2017;18(3):548. https://doi.org/10.3390/ijms18030548</mixed-citation><mixed-citation xml:lang="en">Keefe KM, Sheikh IS, Smith GM. Targeting Neurotrophins to Specifi c Populations of Neurons: NGF, BDNF, and NT-3 and Their Relevance for Treatment of Spinal Cord Injury. International Journal of Molecular Sciences. 2017;18(3):548. https://doi. org/10.3390/ijms18030548</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lu P, Blesch A, Tuszynski MH. Neurotrophism without neurotropism: BDNF promotes survival but not growth of lesioned corticospinal neurons. J Comp Neurol. 2001 Aug 6;436(4):456–70. https://doi.org/10.1002/cne.1080</mixed-citation><mixed-citation xml:lang="en">Lu P, Blesch A, Tuszynski MH. Neurotrophism without neurotropism: BDNF promotes survival but not growth of lesioned corticospinal neurons. J Comp Neurol. 2001 Aug 6;436(4):456–70. https://doi.org/10.1002/cne.1080</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sasaki M, Radtke C, Tan AM, Zhao P, Hamada H, Houkin K, Honmou O, Kocsis JD. BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. J Neurosci. 2009 Nov 25;29(47):14932–41 https://doi.org/10.1523/JNEUROSCI.2769-09.2009</mixed-citation><mixed-citation xml:lang="en">Sasaki M, Radtke C, Tan AM, Zhao P, Hamada H, Houkin K, Honmou O, Kocsis JD. BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. J Neurosci. 2009 Nov 25;29(47):14932–41 https://doi.org/10.1523/JNEUROSCI.2769-09.2009</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Brock JH, Rosenzweig ES, Blesch A, Moseanko R, Havton LA, Edgerton VR, Tuszynski MH. Local and remote growth factor eff ects after primate spinal cord injury. J Neurosci. 2010 Jul 21;30(29):9728–37. https://doi.org/10.1523/JNEUROSCI.1924-10.2010</mixed-citation><mixed-citation xml:lang="en">Brock JH, Rosenzweig ES, Blesch A, Moseanko R, Havton LA, Edgerton VR, Tuszynski MH. Local and remote growth factor eff ects after primate spinal cord injury. J Neurosci. 2010 Jul 21;30(29):9728–37. https://doi.org/10.1523/JNEUROSCI.1924-10.2010</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science. 1990 Mar 23;247(4949 Pt 1):1446–51. https://doi.org/10.1126/science.247.4949.1446</mixed-citation><mixed-citation xml:lang="en">Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science. 1990 Mar 23;247(4949 Pt 1):1446–51. https://doi.org/10.1126/science.247.4949.1446</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Schnell L, Schneider R, Kolbeck R, Barde YA, Schwab ME. Neurotrophin-3 enhances sprouting of corticospinal tract during development and after adult spinal cord lesion. Nature. 1994 Jan 13;367(6459):170–3. https://doi.org/10.1038/367170a0</mixed-citation><mixed-citation xml:lang="en">Schnell L, Schneider R, Kolbeck R, Barde YA, Schwab ME. Neurotrophin-3 enhances sprouting of corticospinal tract during development and after adult spinal cord lesion. Nature. 1994 Jan 13;367(6459):170–3. https://doi.org/10.1038/367170a0</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gao Z, Feng Y, Ju H. The Diff erent Dynamic Changes of Nerve Growth Factor in the Dorsal Horn and Dorsal Root Ganglion Leads to Hyperalgesia and Allodynia in Diabetic Neuropathic Pain. Pain Physician. 2017 May;20(4):551–561. Available at: https://www.painphysicianjournal.com/current/pdf?article=NDQxOA%3D%3 D&amp;journal=105</mixed-citation><mixed-citation xml:lang="en">Gao Z, Feng Y, Ju H. The Diff erent Dynamic Changes of Nerve Growth Factor in the Dorsal Horn and Dorsal Root Ganglion Leads to Hyperalgesia and Allodynia in Diabetic Neuropathic Pain. Pain Physician. 2017 May;20(4):551–561. Available at: https://www.painphysicianjournal.com/current/pdf?article=NDQxOA%3D%3 D&amp;journal=105</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, Navia BA, Schifi tto G, Katzenstein D, Rask C, Zaborski L, Smith ME, Shriver S, Millar L, Cliff ord DB, Karalnik IJ. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology. 2000 Mar 14;54(5):1080–8. https://doi.org/10.1212/wnl.54.5.1080</mixed-citation><mixed-citation xml:lang="en">McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, Navia BA, Schifi tto G, Katzenstein D, Rask C, Zaborski L, Smith ME, Shriver S, Millar L, Cliff ord DB, Karalnik IJ. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology. 2000 Mar 14;54(5):1080–8. https://doi.org/10.1212/wnl.54.5.1080</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Tep C., Lim T.H., Ko P.O., Getahun S., Ryu J.C., Goettl V.M., Massa S.M., Basso M., Longo F.M., Yoon S.O. Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury. J. Neurosci. 2013, 33, 397–410 doi: 10.1523/JNEUROSCI.0399-12.2013</mixed-citation><mixed-citation xml:lang="en">Tep C., Lim T.H., Ko P.O., Getahun S., Ryu J.C., Goettl V.M., Massa S.M., Basso M., Longo F.M., Yoon S.O. Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury. J. Neurosci. 2013, 33, 397–410 doi: 10.1523/JNEUROSCI.0399-12.2013</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Pehar M., Cassina P., Vargas M.R., Xie Y., Beckman J.S., Massa S.M., Longo F.M., Barbeito L. Modulation of p75-dependent motor neuron death by a small non-peptidyl mimetic of the neurotrophin loop 1 domain. Eur. J. Neurosci. 2006, 24, 1575– 1580. doi: 10.1111/j.1460-9568.2006.05040.x</mixed-citation><mixed-citation xml:lang="en">Pehar M., Cassina P., Vargas M.R., Xie Y., Beckman J.S., Massa S.M., Longo F.M., Barbeito L. Modulation of p75-dependent motor neuron death by a small non-peptidyl mimetic of the neurotrophin loop 1 domain. Eur. J. Neurosci. 2006, 24, 1575– 1580. doi: 10.1111/j.1460-9568.2006.05040.x</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Numakawa T., Odaka H. The Role of Neurotrophin Signaling in Age-Related Cognitive Decline and Cognitive Diseases. Int. J. Mol. Sci. 2022, 23, 7726. https://doi.org/10.3390/ijms23147726</mixed-citation><mixed-citation xml:lang="en">Numakawa T., Odaka H. The Role of Neurotrophin Signaling in Age-Related Cognitive Decline and Cognitive Diseases. Int. J. Mol. Sci. 2022, 23, 7726. https://doi.org/10.3390/ijms23147726</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">McPhee GM, Downey LA, Stough C. Neurotrophins as a reliable biomarker for brain function, structure and cognition: A sys tematic review and meta-analysis. Neurobiol Learn Mem. 2020 Nov;175:107298. https://doi.org/10.1016/j.nlm.2020.107298</mixed-citation><mixed-citation xml:lang="en">McPhee GM, Downey LA, Stough C. Neurotrophins as a reliable biomarker for brain function, structure and cognition: A sys tematic review and meta-analysis. Neurobiol Learn Mem. 2020 Nov;175:107298. https://doi.org/10.1016/j.nlm.2020.107298</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR. The BDNF val66met polymorphism aff ects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003 Jan 24;112(2):257–69. https://doi.org/10.1016/s0092-8674(03)00035-7</mixed-citation><mixed-citation xml:lang="en">Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR. The BDNF val66met polymorphism aff ects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003 Jan 24;112(2):257–69. https://doi.org/10.1016/s0092-8674(03)00035-7</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Gao L, Zhang Y, Sterling K, Song W. Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential. Transl Neurodegener 2022;11,4. https://doi.org/10.1186/s40035-022-00279-0</mixed-citation><mixed-citation xml:lang="en">Gao L, Zhang Y, Sterling K, Song W. Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential. Transl Neurodegener 2022;11,4. https://doi.org/10.1186/s40035-022-00279-0</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Braskie MN, Kohannim O, Jahanshad N, Chiang MC, Barysheva M, Toga AW, Ringman JM, Montgomery GW, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Thompson PM. Relation between variants in the neurotrophin receptor gene, NTRK3, and white matter integrity in healthy young adults. Neuroimage 2013;82:146–53. 76. https://doi.org/10.1016/j.neuroimage.2013.05.095</mixed-citation><mixed-citation xml:lang="en">Braskie MN, Kohannim O, Jahanshad N, Chiang MC, Barysheva M, Toga AW, Ringman JM, Montgomery GW, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Thompson PM. Relation between variants in the neurotrophin receptor gene, NTRK3, and white matter integrity in healthy young adults. Neuroimage 2013;82:146–53. 76. https://doi.org/10.1016/j.neuroimage.2013.05.095</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Otnaess MK, Djurovic S, Rimol LM, Kulle B, Kähler AK, Jönsson EG, Agartz I, Sundet K, Hall H, Timm S, Hansen T, Callicott JH, Melle I, Werge T, Andreassen OA.Evidence for a possible association of neurotrophin receptor (NTRK3) gene polymorphisms with hippocampal function and schizophrenia. Neurobiol Dis 2009;34:518–24 https://doi.org/10.1016/j.nbd.2009.03.011</mixed-citation><mixed-citation xml:lang="en">Otnaess MK, Djurovic S, Rimol LM, Kulle B, Kähler AK, Jönsson EG, Agartz I, Sundet K, Hall H, Timm S, Hansen T, Callicott JH, Melle I, Werge T, Andreassen OA.Evidence for a possible association of neurotrophin receptor (NTRK3) gene polymorphisms with hippocampal function and schizophrenia. Neurobiol Dis 2009;34:518–24 https://doi.org/10.1016/j.nbd.2009.03.011</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Sanwald, S, Montag, C, Kiefer M. Depressive Emotionality Moderates the Infl uence of the BDNF Val66Met Polymorphism on Executive Functions and on Unconscious Semantic Priming. J Mol Neurosci 2020;70, 699–712. https://doi.org/10.1007/s12031-020-01479-x</mixed-citation><mixed-citation xml:lang="en">Sanwald, S, Montag, C, Kiefer M. Depressive Emotionality Moderates the Infl uence of the BDNF Val66Met Polymorphism on Executive Functions and on Unconscious Semantic Priming. J Mol Neurosci 2020;70, 699–712. https://doi.org/10.1007/s12031-020- 01479-x</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Quan R, Wu Z, Guo W, He L, Fang P, Gong P. The BDNF Val66Met polymorphism impacts victim’s moral emotions following interpersonal transgression. Scand J Psychol. 2021 Feb;62(1):7– 12. https://doi.org/10.1111/sjop.12678</mixed-citation><mixed-citation xml:lang="en">Quan R, Wu Z, Guo W, He L, Fang P, Gong P. The BDNF Val66Met polymorphism impacts victim’s moral emotions following interpersonal transgression. Scand J Psychol. 2021 Feb;62(1):7– 12. https://doi.org/10.1111/sjop.12678</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Yanlong Liu, Dongsheng Yu, Xiaofang Wang, Xiaohua Tan, Xianming Luo, Hongzhen Fan, Yimin Kang, Jian Xiao, Xiaokun Li, Fan Wang. Is Cerebrospinal Fluid Fibroblast Growth Factor 19 (FGF19) a mood regulator? Neuropsychiatry 2017;7(2):126–130 https://doi.org/10.4172/Neuropsychiatry.1000187</mixed-citation><mixed-citation xml:lang="en">Yanlong Liu, Dongsheng Yu, Xiaofang Wang, Xiaohua Tan, Xianming Luo, Hongzhen Fan, Yimin Kang, Jian Xiao, Xiaokun Li, Fan Wang. Is Cerebrospinal Fluid Fibroblast Growth Factor 19 (FGF19) a mood regulator? Neuropsychiatry 2017;7(2):126–130 https://doi.org/10.4172/Neuropsychiatry.1000187</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Cubillos S, Engmann O, Brancato A. BDNF as a Mediator of Antidepressant Response: Recent Advances and Lifestyle Interactions. Int J Mol Sci. 2022 Nov 21;23(22):14445. https://doi.org/10.3390/ijms232214445</mixed-citation><mixed-citation xml:lang="en">Cubillos S, Engmann O, Brancato A. BDNF as a Mediator of Antidepressant Response: Recent Advances and Lifestyle Interactions. Int J Mol Sci. 2022 Nov 21;23(22):14445. https://doi.org/10.3390/ ijms232214445</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Arosio B, Guerini FR, Voshaar RCO, Aprahamian I. Blood BrainDerived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective? Front Behav Neurosci. 2021 Feb 12;15:626906. https://doi.org/10.3389/fnbeh.2021.626906</mixed-citation><mixed-citation xml:lang="en">Arosio B, Guerini FR, Voshaar RCO, Aprahamian I. Blood BrainDerived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective? Front Behav Neurosci. 2021 Feb 12;15:626906. https://doi.org/10.3389/fnbeh.2021.626906</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Deltheil T, Guiard BP, Guilloux JP, Nicolas L, Deloménie C, Repérant C, Le Maitre E, Leroux-Nicollet I, Benmansour S, Coudoré F, David DJ, Gardier AM. Consequences of changes in BDNF levels on serotonin neurotransmission, 5-HT transporter expression and function: studies in adult mice hippocampus. Pharmacol Biochem Behav. 2008 Aug;90(2):174–83. https://doi.org/10.1016/j.pbb.2007.09.018</mixed-citation><mixed-citation xml:lang="en">Deltheil T, Guiard BP, Guilloux JP, Nicolas L, Deloménie C, Repérant C, Le Maitre E, Leroux-Nicollet I, Benmansour S, Coudoré F, David DJ, Gardier AM. Consequences of changes in BDNF levels on serotonin neurotransmission, 5-HT transporter expression and function: studies in adult mice hippocampus. Pharmacol Biochem Behav. 2008 Aug;90(2):174–83. https://doi.org/10.1016/j.pbb.2007.09.018</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Allen AP, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G, Scott L, McLoughlin DM, Cryan JF, Dinan TG, Clarke G. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. J Aff ect Disord. 2015 Nov1;86:306–11. https://doi.org/10.1016/j.jad.2015.06.033</mixed-citation><mixed-citation xml:lang="en">Allen AP, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G, Scott L, McLoughlin DM, Cryan JF, Dinan TG, Clarke G. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. J Aff ect Disord. 2015 Nov1;86:306–11. https://doi.org/10.1016/j.jad.2015.06.033</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Castrén E, Monteggia L M. Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. Biological Psychiatry: Volume 90, Issue 2, 15 July 2021, P. 128–136. https://doi.org/10.1016/j.biopsych.2021.05.008</mixed-citation><mixed-citation xml:lang="en">Castrén E, Monteggia L M. Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. Biological Psychiatry: Volume 90, Issue 2, 15 July 2021, P. 128–136. https:// doi.org/10.1016/j.biopsych.2021.05.008</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Yang T, Nie Z, Shu H, Kuang Y, Chen X, Cheng J, Yu S and Liu H. The Role of BDNF on Neural Plasticity in Depression. Front. Cell. Neurosci.2020;14:82. https://doi.org/10.3389/fncel.2020.00082</mixed-citation><mixed-citation xml:lang="en">Yang T, Nie Z, Shu H, Kuang Y, Chen X, Cheng J, Yu S and Liu H. The Role of BDNF on Neural Plasticity in Depression. Front. Cell. Neurosci.2020;14:82. https://doi.org/10.3389/fncel.2020.00082</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Miyanishi H, Nitta A. A Role of BDNF in the Depression Pathogenesis and a Potential Target as Antidepressant: The Modulator of Stress Sensitivity “Shati/Nat8l-BDNF System” in the Dorsal Striatum. Pharmaceuticals. 2021;14(9):889. https://doi.org/10.3390/ph14090889</mixed-citation><mixed-citation xml:lang="en">Miyanishi H, Nitta A. A Role of BDNF in the Depression Pathogenesis and a Potential Target as Antidepressant: The Modulator of Stress Sensitivity “Shati/Nat8l-BDNF System” in the Dorsal Striatum. Pharmaceuticals. 2021;14(9):889. https://doi.org/10.3390/ph14090889</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Nazareth, A. M. BDNF, A Focus to Major Depression. Open Journal of Psychology, 2021;1(1):10–21. DOI: 10.31586/ojp.2021.161</mixed-citation><mixed-citation xml:lang="en">Nazareth, A. M. BDNF, A Focus to Major Depression. Open Journal of Psychology, 2021;1(1):10–21. DOI: 10.31586/ojp.2021.161</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">De Miranda AS, de Barros JLVM, Teixeira AL. Is neurotrophin-3 (NT-3): a potential therapeutic target for depression and anxiety? Expert Opin Ther Targets. 2020 Dec;24(12):1225–1238. doi: 10.1080/14728222.2020.1846720</mixed-citation><mixed-citation xml:lang="en">De Miranda AS, de Barros JLVM, Teixeira AL. Is neurotrophin-3 (NT-3): a potential therapeutic target for depression and anxiety? Expert Opin Ther Targets. 2020 Dec;24(12):1225–1238. doi: 10.1080/14728222.2020.1846720</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Samerria S, Radovick S. The Role of Insulin-like Growth Factor-1 (IGF-1) in the Control of Neuroendocrine Regulation of Growth. Cells. 2021;10(10):2664. https://doi.org/10.3390/cells10102664</mixed-citation><mixed-citation xml:lang="en">Al-Samerria S, Radovick S. The Role of Insulin-like Growth Factor-1 (IGF-1) in the Control of Neuroendocrine Regulation of Growth. Cells. 2021;10(10):2664. https://doi.org/10.3390/cells10102664</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Clemmons DR. Role of IGF-binding proteins in regulating IGF responses to changes in metabolism. J Mol Endocrinol. 2018 Jul;61(1):T139-T169. https://doi.org/10.1530/JME-18-0016</mixed-citation><mixed-citation xml:lang="en">Clemmons DR. Role of IGF-binding proteins in regulating IGF responses to changes in metabolism. J Mol Endocrinol. 2018 Jul;61(1):T139-T169. https://doi.org/10.1530/JME-18-0016</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Vitale G, Pellegrino G, Vollery M, Hofl and LJ. ROLE of IGF1 System in the Modulation of Longevity: Controversies and New Insights From a Centenarians’ Perspective. Front Endocrinol (Lausanne). 2019 Feb 1;10:27. https://doi.org/10.3389/fendo.2019.00027</mixed-citation><mixed-citation xml:lang="en">Vitale G, Pellegrino G, Vollery M, Hofl and LJ. ROLE of IGF1 System in the Modulation of Longevity: Controversies and New Insights From a Centenarians’ Perspective. Front Endocrinol (Lausanne). 2019 Feb 1;10:27. https://doi.org/10.3389/fendo.2019.00027</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller PL, Pritchett CE, Wiechman TN, Zharikov A, Hajnal A. Antidepressant-like eff ects of insulin and IGF-1 are mediated by IGF-1 receptors in the brain. BrainResearch Bulletin. 2018;143:27– 35. https://doi.org/10.1016/j.brainresbull.2018.09.017</mixed-citation><mixed-citation xml:lang="en">Mueller PL, Pritchett CE, Wiechman TN, Zharikov A, Hajnal A. Antidepressant-like eff ects of insulin and IGF-1 are mediated by IGF-1 receptors in the brain. BrainResearch Bulletin. 2018;143:27– 35. https://doi.org/10.1016/j.brainresbull.2018.09.017</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Askmyr M, White KE, Jovic T, King HA, Quach JM, Maluenda AC, Baker EK, Smeets MF, Walkley CR, Purton LE. Ciliary neurotrophic factor has intrinsic and extrinsic roles in regulating B cell differentiation and bone structure. Sci Rep 2015;5:15529. https://doi.org/10.1038/srep15529</mixed-citation><mixed-citation xml:lang="en">Askmyr M, White KE, Jovic T, King HA, Quach JM, Maluenda AC, Baker EK, Smeets MF, Walkley CR, Purton LE. Ciliary neurotrophic factor has intrinsic and extrinsic roles in regulating B cell differentiation and bone structure. Sci Rep 2015;5:15529. https://doi.org/10.1038/srep15529</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ. Ciliary neurotrophic factor activates leptinlike pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA. 2001 Apr 10;98(8):4652–7. https://doi.org/10.1073/pnas.061034298</mixed-citation><mixed-citation xml:lang="en">Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ. Ciliary neurotrophic factor activates leptinlike pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA. 2001 Apr 10;98(8):4652–7. https://doi.org/10.1073/pnas.061034298</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Cintrón-Colón AF, Almeida-Alves G, Boynton AM, Spitsbergen JM. GDNF synthesis, signaling, and retrograde transport in motor neuron. Cell and Tissue Research. 2020;382(1):47–56. https://doi.org/10.1007/s00441-020-03287-6</mixed-citation><mixed-citation xml:lang="en">Cintrón-Colón AF, Almeida-Alves G, Boynton AM, Spitsbergen JM. GDNF synthesis, signaling, and retrograde transport in motor neuron. Cell and Tissue Research. 2020;382(1):47–56. https://doi.org/10.1007/s00441-020-03287-6</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Manfredsson FP, Polinski NK, Subramanian T, Boulis N, Wakeman DR, Mandel RJ. The Future of GDNF in Parkinson’s Disease. Front Aging Neurosci. 2020 Dec 7;12:593572. https://doi.org/10.3389/fnagi.2020.593572</mixed-citation><mixed-citation xml:lang="en">Manfredsson FP, Polinski NK, Subramanian T, Boulis N, Wakeman DR, Mandel RJ. The Future of GDNF in Parkinson’s Disease. Front Aging Neurosci. 2020 Dec 7;12:593572. https://doi.org/10.3389/fnagi.2020.593572</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Meir M, Burkard N, Ungewiß H, Diefenbacher M, Flemming S, Kannapin F, Germer CT, Schweinlin M, Metzger M, Waschke J, Schlegel N. Neurotrophic factor GDNF regulates intestinal barrier function in inflammatory bowel disease. J Clin Invest. 2019 Jun 17;129(7):2824–2840. https://doi.org/10.1172/JCI120261</mixed-citation><mixed-citation xml:lang="en">Meir M, Burkard N, Ungewiß H, Diefenbacher M, Flemming S, Kannapin F, Germer CT, Schweinlin M, Metzger M, Waschke J, Schlegel N. Neurotrophic factor GDNF regulates intestinal barrier function in inflammatory bowel disease. J Clin Invest. 2019 Jun 17;129(7):2824–2840. https://doi.org/10.1172/JCI120261</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Tao L, Ma W, Wu L, Xu M, Yang Y, Zhang W, Sha W, Li H, Xu J, Feng R, Xue D, Zhang J, Dooley S, Seki E, Liu P, Liu C. Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signaling. Gut. 2019 Dec;68(12):2214–2227. https://doi.org/10.1136/gutjnl-2018-317872</mixed-citation><mixed-citation xml:lang="en">Tao L, Ma W, Wu L, Xu M, Yang Y, Zhang W, Sha W, Li H, Xu J, Feng R, Xue D, Zhang J, Dooley S, Seki E, Liu P, Liu C. Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signaling. Gut. 2019 Dec;68(12):2214–2227. https://doi.org/10.1136/gutjnl-2018-317872</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
